Therapy provides significant survival benefit in second-line metastatic
hormone-refractory prostate cancer in combination with prednisone.
LAVAL, QC, Oct. 4, 2012 /CNW Telbec/ - Sanofi is pleased to announce
that the provinces of Alberta, Saskatchewan and Ontario have listed
JEVTANA® (cabazitaxel) on their respective provincial formulary so that
it is now eligible for reimbursement for patients with advanced
prostate cancer. JEVTANA® (cabazitaxel) is indicated as a second line treatment of castration
resistant (hormone refractory) metastatic prostate cancer (mHRPC) in
combination with prednisone in patients who have received prior
treatment with a docetaxel containing regimen.
"JEVTANA fills a critical treatment gap, since it is the novel treatment
approved for patients with this stage of metastatic hormone-refractory
prostate cancer. The ability to access JEVTANA and to know that
Alberta, Saskatchewan and Ontario are funding the treatment is a major
gain for men dealing with the disease and their families," said Dr.
Stan Glezer, Vice President of Evidence, Value and Access. "Sanofi is
strongly committed to bringing innovative therapies to the cancer
community and to working in cooperation with the provincial health
agencies to demonstrate the value of medicine for the patients and
contribute to the sustainability of the healthcare system."
The combination of JEVTANA® and prednisone is the first and only
chemotherapy to have shown a significant survival benefit for men with
mHRPC previously treated with a docetaxel-containing regimen.
Reimbursement for prescription drugs is not mandated by the Canada Health Act or any other federal legislation. Provincial governments independently
establish reimbursement plans.
"We trust other provinces will follow the lead of Alberta, Saskatchewan
and Ontario and approve coverage of this treatment option," added Dr.
Glezer. "JEVTANA is an important therapy addition for patients living
with mHRPC and helps healthcare professionals in their efforts to treat
those patients. Hopefully the availability of a drug like JEVTANA® (cabazitaxel) will signal the start of a new, more effective approach to
help these patients access the treatment."
"Access and availability in Alberta to new options such as JEVTANA® can provide patients with a better chance of survival when dealing with
such a difficult illness," concluded Bob Shiell, Executive Director,
Prostate Cancer Canada Network (PCCN) Calgary.
JEVTANA® (cabazitaxel) is approved as a second-line treatment option for
metastatic castration resistant (hormone-refractory) prostate cancer
(mCRPC).[i] JEVTANA® is a chemotherapy compound used with the steroid medicine
prednisone or prednisolone to treat people with mCRPC previously
treated with a docetaxel-containing treatment regimen.[ii]
Jevtana® is a registered trademark of Sanofi.
About Prostate Cancer
Worldwide, prostate cancer ranks third in cancer incidence and sixth in
cancer mortality in men. In the U.S., prostate cancer remains the
second most common cause of cancer death among men after lung cancer.
In Canada, one man in seven men will develop prostate cancer. It is the
most frequently diagnosed cancer in men and its incidence has increased
by 30 percent since 1988. While it is most commonly diagnosed after age
70, prostate cancer can also occur in men in their forties and fifties. [ii1] For many patients with prostate cancer, their disease continues to
progress despite prior treatment - including surgical and/or hormonal
castration followed by chemotherapy. Metastatic prostate cancer
indicates that the cancer has spread to the lymph nodes or other parts
of the body, particularly the bones. Castration
resistant/hormone-refractory prostate cancer means that the cancer has
continued to grow despite the suppression of male hormones that fuel
the growth of prostate cancer cells. An estimated 10-20% of patients
with prostate cancer are diagnosed when the cancer has already
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients' needs.
Sanofi has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new
Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York
Sanofi companies in Canada include sanofi-aventis Canada Inc.
(pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health
(health and beauty), Genzyme (rare diseases) and Merial (animal
health). Together they employ more than 1,700 people, mainly in the
greater Montreal and Toronto areas. In 2011 Sanofi companies invested
$151.7 million in R&D in Canada, creating jobs, business and
opportunity throughout the country. For additional information, please
visit http://www.sanofi.ca .
[i] "About Jevtana." Sanofi-aventis Oncology. Available online:
[ii] "About Jevtana." Sanofi-aventis Oncology. Available online:
[iii] Prostate Cancer: Understand the Disease and its Treatment: Saad F,
McCormack M; Annika Parance Publishing; 2012, p. 25
For further information:
Communications Consultant, Sanofi Canada